Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

GENE - CHEMICAL INTERACTIONS REPORT

RGD ID: 2200
Species: Rattus norvegicus
RGD Object: Gene
Symbol: Bcl2l1
Name: Bcl2-like 1
Acc ID: CHEBI:52717
Term: bortezomib
Definition: L-Phenylalaninamide substituted at the amide nitrogen by a 1-(dihydroxyboranyl)-3-methylbutyl group and at N(alpha) by a pyrazin-2-ylcarbonyl group. It is a dipeptidyl boronic acid that reversibly inhibits the 26S proteasome.
Chemical ID: MESH:D000069286
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction is comprised of a complex set of reactions and/or regulatory events, possibly involving additional chemicals and/or gene products.
Object SymbolQualifierEvidenceWithReferenceSourceNotesOriginal Reference(s)
Bcl2l1decreases expressionISOBCL2L1 (Homo sapiens)6480464CTDBortezomib results in decreased expression of BCL2L1 mRNA; Bortezomib results in decreased expression of BCL2L1 proteinPMID:15543232 PMID:16446371 PMID:16617327 PMID:16904634 PMID:17327374 PMID:20051518
Bcl2l1decreases response to substanceISOBCL2L1 (Homo sapiens)6480464CTDBCL2L1 protein results in decreased susceptibility to BortezomibPMID:15781649 PMID:19100720
Bcl2l1increases cleavageISOBCL2L1 (Homo sapiens)6480464CTDBortezomib results in increased cleavage of BCL2L1 proteinPMID:16118318
Bcl2l1increases expressionISOBCL2L1 (Homo sapiens)6480464CTDBortezomib results in increased expression of BCL2L1 proteinPMID:17326159
Bcl2l1multiple interactionsISOBCL2L1 (Homo sapiens)6480464CTD[alvocidib co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [romidepsin co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [Vorinostat co-treated with Bortezomib] results in decreased expression of BCL2L1 protein alternative form; [Vorinostat co-treated with Bortezomib] results in increased expression of BCL2L1 mRNA alternative form; [Vorinostat co-treated with Bortezomib] results in increased expression of BCL2L1 protein alternative form; BCL2L1 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; BCL2L1 protein results in decreased susceptibility to [Bortezomib co-treated with trichostatin A]; Bortezomib promotes the reaction [capillarisin results in decreased expression of BCL2L1 protein]; lonafarnib promotes the reaction [Bortezomib results in increased cleavage of BCL2L1 protein]; SCIO-469 promotes the reaction [Bortezomib results in decreased expression of BCL2L1 protein]; trichostatin A promotes the reaction [Bortezomib results in decreased expression of BCL2L1 mRNA]; trichostatin A promotes the reaction [Bortezomib results in decreased expression of BCL2L1 protein]PMID:15039284 PMID:15781649 PMID:16118318 PMID:16617327 PMID:16904634 PMID:17326159 PMID:17351739 PMID:18223231 PMID:24333736
Go Back to source page   Continue to Ontology report